(P018) Micronucleus Score in Buccal Smear of Premalignant Lesions of Oral Cancers in Smokers

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Oral squamous cell carcinoma encompasses 90% of all oral malignancies. It is considered the sixth most common malignancy and is a major cause of cancer morbidity and mortality worldwide. Early detection of premalignant lesions or cancerous oral lesions would improve the survival to a greater extent.

Rijuneeta Gupta, MS, MD, Aniruddha Sarkar, MS, MD, Ashok Gupta, MS, MD, Pranab Dey, MD, Uma Nahar, MD; Department of Ear Nose and Throat, Post Graduate Institute of Medical Education and Research (PGIMER)

Introduction: Oral squamous cell carcinoma encompasses 90% of all oral malignancies. It is considered the sixth most common malignancy and is a major cause of cancer morbidity and mortality worldwide. Early detection of premalignant lesions or cancerous oral lesions would improve the survival to a greater extent.

The micronucleus (MN) is the small fragment of the nucleus situated around the periphery of the main nucleus. The number of micronucleated cells (MNCs) per 1,000 epithelial cells in oil immersion magnification (1,000 ×) is known as MN score. The MN score from buccal mucosa may be helpful in detecting premalignant lesions of the oral cavity in smokers.

Objectives: To evaluate the role of MN score in buccal smears of premalignant lesions of the oral cavity in smokers.

Materials and Methods: It was a prospective cross-sectional study including 60 patients with ages ranging from 15–70 years. They were divided into three groups. Group 1 (control) included 20 nonsmokers with lesions other than premalignant lesions, Group 2 included 20 smokers with lesions other than premalignant lesions, and Group 3 included 20 smokers with premalignant conditions of the oral cavity.

In each patient, smears were taken from the lesion with the help of sterile, clean, blunt scalpel blades. Smears were immediately seen under a fluorescent microscope, and MNCs were counted per 1,000 epithelial cells. In all patients, a biopsy was also done.

Chronic alcoholics, postradiotherapy cases, and cases exposed to any cytotoxic drug were excluded from the study.

Observations: Overall, 85% was male and 15% was female. Mean MN scores in all groups (acridine orange stain) were 0.1052, 0.2725, and 0.855, respectively. Mean scores for Groups 1, 2, and 3 in Papanicolaou staining were 0.1365, 0.395, and 1.12, respectively. Pearson’s correlation coefficient was done between smoking and MN score. Smoking was found to be positively correlated to MN score in both Papanicolaou and acridine orange smears.

Histopathological examination showed no evidence of malignancy in Groups 1 and 2. Group 3 showed histopathological evidence of leukoplakia (85%), lichen planus (5%), keratosis (5%), and papilloma (5%).

MN score was not statistically significant between Group 1 and Group 2 (P > .5). However, MN score was highly statistically significant (P < .0001) between Group 2 and Group 3 and also between Group 1 and Group 3.

Conclusions: We found a gradual increase in MN score from nonsmokers with no premalignant lesions (Group 1) to smokers with no premalignant lesions (Group 2) and smokers with premalignant lesions (Group 3). MN scoring can be used as a biomarker for screening premalignant conditions.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content